GDTC
CytoMed Therapeutics Limited (GDTC) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Growth (D). The rating has held at C+ for 14 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B- (2.9) | D (1.5) | B+ (3.8) | B- (3.0) | C+ (2.6) | C+ (2.8) |
| 2026-11-05 | B- (2.9) | D (1.5) | B+ (3.8) | B- (2.9) | C+ (2.7) | C+ (2.7) |
| 2026-10-29 | B- (2.9) | D (1.4) | B+ (3.8) | C (2.3) | C+ (2.7) | C+ (2.6) |
| 2026-10-22 | B- (2.9) | D (1.4) | B+ (3.8) | C (2.4) | C+ (2.6) | C+ (2.6) |
| 2026-10-15 | B- (2.9) | D (1.4) | B+ (3.8) | C- (2.0) | C+ (2.6) | C+ (2.6) |